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ABSTRACT
Background
Suppression of prostacyclin (PGI2) is implicated in the cardiovascular hazard from inhibitors
of cyclooxygenase (COX)-2. Furthermore, estrogen confers atheroprotection via COX-2–
dependent PGI2 in mice, raising the possibility that COX inhibitors may undermine the
cardioprotection, suggested by observational studies, of endogenous or exogenous estrogens.
Methods and Findings
To identify an interaction between hormone therapy (HT) and COX inhibition, we measured a
priori the association between concomitant nonsteroidal anti-inflammatory drugs (NSAIDs),
excluding aspirin, in peri- and postmenopausal women on HT and the incidence of myocardial
infarction (MI) in a population-based epidemiological study. The odds ratio (OR) of MI in 1,673
individuals and 7,005 controls was increased from 0.66 (95% confidence interval [CI] 0.50–0.88)
when taking HT in the absence of traditional (t)NSAIDs to 1.50 (95% CI 0.85–2.64) when taking
the combination of HT and tNSAIDs, resulting in a significant (p , 0.002) interaction. The OR
when taking aspirin at doses of 150 mg/d or more was 1.41 (95% CI 0.47–4.22). However, a
similar interaction was not observed with other commonly used drugs, including lower doses
of aspirin, which target preferentially COX-1.
Conclusions
Whether estrogens confer cardioprotection remains controversial. Such a benefit was
observed only in perimenopausal women in the only large randomized trial designed to
address this issue. Should such a benefit exist, these results raise the possibility that COX
inhibitors may undermine the cardioprotective effects of HT.
The Editors’ Summary of this article follows the references.
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Premenopausal women are less susceptible to myocardial
infarction (MI) and stroke than are males of the same age
group, an advantage that is lost after menopause [1].
However, the mechanism by which female gender affords
cardioprotection is unclear. Despite the cardiovascular
advantage of premenopausal women, it has been difﬁcult to
identify a cardioprotective effect of hormone therapy (HT) in
postmenopausal women [2]. We recently found in mice that
estrogen acts via its ERa receptor to up-regulate COX-2–
dependent prostacyclin (PGI2) formation which, acting via its
receptor (the I prostanoid receptor) constrains both platelet
activation and oxidant stress. Indeed, deletion of the I
prostanoid receptor undermined substantially the vascular
beneﬁt of estrogen therapy in ovariectomized mice rendered
prone to atherogenesis by deletion of the low-density
lipoprotein receptor [3].
These observations prompted us to address the possibility
that the failure to detect a beneﬁt from estrogen might be
partly attributable to a pharmacodynamic interaction with
inhibitors of COX-2, the major source of PGI2 in vivo.
Sufﬁcient information is currently unavailable to address this
question for selective inhibitors of COX-2. However, tradi-
tional (t) nonsteroidal anti-inﬂammatory drugs (NSAIDs),
such as ibuprofen, variably inhibit both COX-1 and COX-2,
unlike low-dose aspirin, which targets preferentially, albeit
not exclusively, COX-1 [4,5]. The objective of the current
study is to provide a preliminary estimate of the interaction,
in a general population setting, between tNSAIDs and HT on
the occurrence of acute myocardial infarction (AMI) and
death from coronary heart disease (CHD).
Methods
Source of Data
The General Practice Research Database contains compu-
terized medical information entered systematically by general
practitioners (GPs) in the UK and sent anonymously to the
Medicines and Healthcare Products Regulatory Agency [6].
The information recorded includes demographic data, out-
patient clinical diagnoses, consultant referrals, hospital
admissions, and prescriptions. More than 90% of all referrals
present in the manual records in GPs’ ofﬁces are entered into
computer ﬁles with a code that reﬂects the clinical diagnosis.
Prescriptions are generated directly from the GP’s computer
and entered into the patient’s computerized ﬁle. The term
‘‘tNSAIDs’’ included the following agents: aceclofenac,
acemetacin, azapropazone, diclofenac, diﬂunisal, etodolac,
fenbufen, fenoprofen, ﬂurbiprofen, ibuprofen, indometha-
cin, ketoprofen, ketorolac, mefenamic acid, meloxican,
nabumetone, naproxen, piroxicam, sulindac, tenoxicam,
and tiaprofenic. There was insufﬁcient information to
explore with precision the interaction at the individual
tNSAID level. tNSAIDs did not include aspirin nor selective
COX-2 inhibitors. The latter were introduced in the UK in
late 2000 when the study period ended. The three most widely
used tNSAIDs (diclofenac, ibuprofen, and naproxen) ac-
counted for 75% of all tNSAID use.
Study Design
We recently evaluated the association between tNSAIDs
and acute MI [7], where more details of the study population
are provided. The results were compatible with the absence of
a major beneﬁcial or detrimental effect of tNSAIDs on the
risk of MI. The study design and methods are described in
detail in this paper. In brief, we identiﬁed all individuals aged
50–84 y on 1 January 1997. We started following up patients
from the ﬁrst day after that date, once they met the criteria of
at least two years’ enrolment with the GP and one year since
the ﬁrst computerized prescription of any drug. That date
was designated as their start date. We excluded patients with
a diagnosis of cancer before the start date. We followed up all
study cohort members from the start date until the earliest
occurrence of one of the following endpoints: a ﬁrst recorded
diagnosis of MI, cancer, death, age 85 y, date of last practice
data collection, or 31 December 2000. We reviewed compu-
terized proﬁles of all patients with a code of MI as well as all
deaths. We used the adapted international standardized
diagnostic criteria to consider an individual as having an
AMI or dying from CHD [8,9]. Ultimately, 4,795 patients were
included and the date of admission to the hospital or the date
of death was treated as index date. All of the women were
included as AMI individuals (n ¼ 1,673) in the present study.
We considered as fatal those individuals who died within the
ﬁrst 30 d after the occurrence of AMI and patients who died
from CHD before reaching the hospital. Therefore in this
study, designed a priori, AMI includes, if not otherwise stated,
both fatal and nonfatal outcomes in the participants. A
random date within the study period was generated for each
of the study cohort members. All individuals with a random
date included in their period of observation (from study
entry to end of follow-up) were eligible as controls. A group
of 20,000 control participants, frequency-matched by age,
sex, and calendar year, was randomly sampled among with the
study cohort. We applied to the controls the same computer-
based exclusion criteria as we applied to AMI indviduals,
using each participant’s random date as his or her index date.
For the present study, we included all women as control
participants (7,005 controls).
Information on coronary risk factors, comorbidities, and
drug utilization was obtained from the database. Hyper-
tension, diabetes, hyperlipidemia, smoking, cardiovascular
disease, arthritis, and recent anemia were considered present
when these speciﬁc diagnoses were registered in the database
before the index date. History of CHD was deﬁned by the
presence of MI and/or angina. Cerebrovascular disease was
deﬁned by the presence of ischemic or hemorrhagic stroke.
Body mass index, expressed in kg/m
2, was calculated from the
registered height and weight. Alcohol intake was used as
directly registered by the GP. We also elicited the partic-
ipants’ use of the health services (visits to the GP, specialist
referrals, and hospital admissions) in the two years before the
index date.
A list of all medications containing estrogens and/or
progestogens recommended for HT and available in the UK
during the study period was extracted from the British
National Formulary. These drugs were grouped into the
following regimens: (a) oral oestrogens; (b) transdermal
oestradiol; (c) oestradiol implant; and (d) tibolone. In
addition, oral oestrogens and transdermal oestradiol were
classiﬁed as opposed (59% of all HT) or unopposed (41% of
all HT) depending on whether a progestin was supplied along
with oestrogens. Exposure to HT was classiﬁed into three
groups: ‘‘current users’’ when the supply of the most recent
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Estrogens and NSAIDsprescription lasted until index date or ended in the year
before the index date; ‘‘past users’’ when it ended more than
one year before the index date; and ‘‘nonusers’’ when there
was no recorded use before the index date. When current use
was restricted to those exposed only in the month before the
index date, the estimate for the interaction was slightly
higher. There was considerable—73%—overlap in the women
considered current users by the two deﬁnitions. The
deﬁnition of current use for all other studied drugs, including
tNSAIDs, was use of the drug in the month before the index
date.
Statistical Analyses
A nested case-control analysis was performed to estimate
the effect of HT as well as the interaction between HT and
tNSAIDs on the risk of MI. We calculated the odds ratio (OR)
and 95% conﬁdence intervals (CIs) of MI using unconditional
logistic regression. All estimates of risk were adjusted for age,
smoking, hypertension, diabetes, obesity, hypercholesterole-
mia, ischemic heart disease, use of low-dose aspirin, and
antihypertensive drugs.
Results
Overall, current use of HT was associated with a reduced
risk of MI with an OR of 0.78 (95% CI 0.61–1.00) (Table 1).
The corresponding OR among long-term users of HT,
deﬁned as exceeding 2 y, was 0.72 (95% CI 0.52–0.99).
However, this suggestion of cardioprotection from HT
disappeared (Figure 1) in women who were taking tNSAIDS
Table 1. Risk of Acute MI in Users of HT by Duration, Users of NSAIDs, and Concomitant Users of HT and NSAIDs
Treatments Treatment Condition Duration Participants (n ¼ 1,673) Controls (n ¼ 7,005) Multivariate OR (95% CI)
a
HT Never used HT 1,494 6,081 1
Current HT use 99 566 0.78 (0.61–1.00)
  2 y 47 232 0.87 (0.61–1.22)
. 2 y 52 334 0.72 (0.52–0.99)
Past HT users 80 358 0.91 (0.69–1.19)
NSAID Never used 596 2,655 1
Current use 223 819 1.11 (0.88–1.38)
Past use 854 3,531 0.95 (0.84–1.08)
HT þ NSAID Never 562 2,394 1
Current HT, no NSAID 71 498 0.64 (0.48–0.85)
Current NSAID, no HT 195 751 1.02 (0.84–1.24)
Current HT and NSAID 28 68 1.71 (1.05–2.78)
aAdjusted for age, history of smoking, hypertension, diabetes, obesity, hypercholesterolemia, ischemic heart disease, use of low-dose aspirin, tNSAIDs, and antihypertensive drugs.
doi:10.1371/journal.pmed.0040157.t001
Figure 1. Acute MI and Current Use of HT by Duration, Stratified for Use of tNSAIDs
*ORs adjusted for age, history of smoking, hypertension, diabetes, obesity, hypercholesterolemia, ischemic heart disease, use of low-dose aspirin, and
antihypertensive drugs. The estimates of OR associated with current use of HT were calculated using non-use of HT as reference group in each of the
three NSAID strata presented.
doi:10.1371/journal.pmed.0040157.g001
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Estrogens and NSAIDsconcomitantly (OR 1.50; 95% CI 0.85–2.64). If tNSAIDs had
not been used in the preceding month (combining the past
users and never users of NSAIDs), use of HT resulted in an
OR of 0.66 (95% CI 0.50–0.88). When we performed a
standard test of interaction, the level of signiﬁcance attained
was p ¼ 0.0012. The ﬁgure also shows that these estimates of
risk did not vary by duration of HT. The interaction was
apparent in women taking both opposed and unopposed
estrogens, with ORs of 1.39 (95% CI 0.65–2.95) and 1.86 (95%
CI 0.79–4.42), respectively. Also, the interaction between HT
and tNSAIDs was already evident within months of starting
the tNSAID and was sustained, irrespective of the duration of
tNSAID therapy or HT (Table 2). Menopausal status is often
lacking in the General Practice Research Database. A
secondary analysis restricted to women older than 55 attained
similar results: use of HT in the absence of tNSAIDs resulted
in an OR of 0.68 (95% CI 0.50–0.93) among women in this age
group. Another subset analysis restricted to women free of
CHD yielded an OR of 1.57 (95% CI 0.78–3.18) among long-
term users of HT taking tNSAIDs concomitantly.
Prompted by these results, we sought the interaction in a
secondary analysis of current and past HT users and in HT
nonusers for patients on low- and high-dose aspirin,
antihypertensives, antidepressants, and gastric acid–suppress-
ing drugs—a further 15 comparisons. Clearly, it is possible
that a signiﬁcant result might be attained amongst such
multiple comparisons by chance. Concomitant use of aspirin
at 75mg/d, which preferentially targets COX-1 for inhibition,
was associated with an OR of 0.71 (95% CI 0.26–1.94)
approximating that in aspirin nonusers (OR 0.77; 95% CI
0.59–1.00). However, the OR of a MI rose to 1.41 (95% CI
0.47–4.22) amongst users of HT with concomitant doses of
aspirin 150 mg/d and above, where coincident inhibition of
COX-2 should be more pronounced. We replicated these
analyses adjusting for health services utilization, and the
results were materially unchanged (unpublished data). We
investigated whether this interaction was speciﬁc to tNSAIDs,
and found that commonly used drugs, such as antihyperten-
sive drugs, acid-suppressing drugs (proton pump inhibitors
and/or histamine II antagonists), and tricyclic antidepressants
failed to reveal an interaction with HT (unpublished data).
Thus, the interaction between COX inhibitors and HT
appeared to be speciﬁc. Also, when we performed a sensitivity
analysis using a one-month time window instead of one year
to deﬁne current use of HT, the OR of HT in women who
were taking tNSAIDS concomitantly further rose to 1.85
(95% CI 1.01–3.41). Although we adjusted for matching
factors (age, sex, calendar time) in our analysis and for a series
of known cardiovascular risk factors, an unrecognized and
therefore unmeasured factor that strongly related both to
concomitant use of HT and NSAIDs on one hand, and to the
risk of MI on the other might theoretically contribute to our
results.
Discussion
The results of this study raise the possibility that
concomitant medication with NSAIDs might undermine a
cardioprotective effect of HT in perimenopausal women.
Mechanistically, this might relate particularly to inhibition of
COX-2. However, the present study pertained to tNSAIDs,
which inhibit COX-2, but vary in their comcomitant
inhibtion of COX-1 and did not include NSAIDs designed
to attain speciﬁc inhibition of COX-2.
Both the pattern of incidence and the manifestation of
vascular disease differ between women and men. Premeno-
pausal women exhibit a diminished burden of vascular
disease compared with males of similar age; this difference
is eclipsed after menopause [1]. Furthermore, the excess
incidence of MI over stroke is more pronounced in men than
in women [10]. Aspirin is effective in the primary prevention
of MI in men [11,12] and in the primary prevention of stroke
in women [10], possibly reﬂecting a true difference in drug
response between the sexes. However, when the absolute
incidence of all events is greater in trials of secondary
prevention, aspirin detectably reduces the incidence of both
MI and thrombotic stroke in both genders [13].
The present study raises the possibility of a drug–drug
interaction with cardiovascular implications involving COX
inhibitors. Much controversy has surrounded the putative
cardioprotective effects of HT reported in observational
studies [14]. Indeed, the only randomized controlled trial
(RCT)—the Women’s Health Initiative (WHI) study—failed to
support this contention overall. While observational studies
have most frequently found an approximate 30% reduction
in CHD amongst users of HT, there was an increase in risk of
CHD in HT users in the ﬁrst years of follow-up in WHI. Some
of the observational studies have limitations, including
healthy user bias, compliance bias, inclusion of a small
number of new initiators of HT, and choice of the reference
Table 2. Risk of Acute MI in Users of HT by Duration Stratified According to Duration of Current tNSAID Use
Duration of Current NSAID Use Duration of Current HT Use Participants (n) Controls (n) Multivariate OR (95% CI)
a
  2 mo Total 53 230
All current users 6 24 2.16 (0.60–7.79)
  2 y 2 11 1.34 (0.20–8.94)
. 2 y 4 13 3.02 (0.65–14.05)
. 2 mo Total 170 589
All current users 22 44 1.59 (0.83–3.03)
  2 y 12 16 1.93 (0.78–4.78)
. 2 y 10 28 1.36 (0.65–3.14)
aAdjusted for age, history of smoking, hypertension, diabetes, obesity, hypercholesterolemia, ischemic heart disease, use of low-dose aspirin, and antihypertensive drugs. The test for trend
does not attain significance (p . 0.05).
doi:10.1371/journal.pmed.0040157.t002
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Estrogens and NSAIDsgroup [15]. Yet, even after adjustment for these methodo-
logical issues, the summary estimate associated with HT use
reﬂects a risk reduction of close to 20% [15].
Generally, when the results of observational studies are in
conﬂict with an RCT, the balance of evidence favors the
latter. While observational studies can control for recognized
variables, they are vulnerable to an imbalanced distribution
of unrecognized variables of relevance to the outcome of the
study. On the other hand, WHI was also affected by some
methodological constraints. The ﬁrst was a differential
detection bias [16]. Close to 40% of those allocated to HT,
but only 7% of those allocated to placebo, were unblinded at
some point during the RCT. The second was the gradual loss
of the baseline comparability between the HT and placebo
arms over time (average 5 y). The third was the limited power
to estimate with precision the apparent protective effect
appearing after long-term HT exposure. However, perhaps
an even more important difference between WHI and other
RCTs of HT and the observational studies is the age of the
women investigated. For example, two-thirds of users in the
WHI were aged 60 y or above at the beginning of the RCT
[17], whereas only about one-ﬁfth of users in the general UK
population were in that age range in the year 2000 [18]. As
summarized recently by Mendelsohn and Karas [19], the age
at which women initiate HT is likely to be critical; evidence
from animal models suggest that beneﬁcial effects of HT in
the cardiovascular system would only be anticipated if it is
initiated before the development of advanced atherosclerosis.
The potential importance of this difference has been high-
lighted by a recent analysis of the WHI data based on patient
age and years since menopause. Women who initiated HT
close to menopause tended to have a reduced risk of coronary
heart disease while risk appeared to increase among women
starting HT more distant from the menopause [20]. Our
studies in mice revealed that loss of PGI2 impacted
particularly on initiation and early development of athero-
sclerosis [3]. Thus, an age-dependent cardiovascular beneﬁt
from HT might both reconcile the apparent discrepancy
between the observational studies and WHI and be consistent
with a pharmacodynamic interaction between HT and
NSAIDs. Furthermore, recent studies in mice indicate that
progesterone, used in combination with estrogen in WHI,
antagonizes the vasoprotective effect of estrogen on anti-
oxidant enzyme and function [21]—the apparent mechanism
disrupted by inhibition of COX-2–dependent PGI2 [3]. Thus,
we felt it most appropriate to seek preliminary evidence for
the clinical importance of these observations in studies of
NSAID use in younger women, in whom observational data
suggest consistently that long-term HT may confer cardio-
vascular beneﬁt. Clearly, additional RCTs will be necessary to
address residual controversies relating to cardioprotection
from HT.
We have reported that estrogen dependent atheroprotec-
tion in mice depends in substantial part on COX-2 derived
PGI2. Scant information is presently available concerning the
combined use of speciﬁc COX–2 inhibitors and HT. However,
we examined a priori a database for an interaction between
tNSAIDs and HT. Generally, the coincident, time-dependent
inhibition of platelet COX-1–derived thromboxane A2 might
be expected, if anything, to mitigate the impact of COX-2
inhibition by the tNSAIDs examined in this study [22]. We do
not have sufﬁcient information to determine the effects of
individual tNSAIDs. However, it is pharmacologically plau-
sible that within this category are drugs that favor inhibition
of COX-2 (e.g. diclofenac), inhibit both COX enzymes
coincidentally over time (e.g. ibuprofen), afford cardiopro-
tection in some individuals (e.g. naproxen), or interact ( e.g.
ibuprofen and naproxen) to undermine cardioprotection
from low-dose aspirin [5,23]. Future studies—ideally an
RCT—will determine whether these properties differentially
inﬂuence an interaction with HT. Similarly, we have
insufﬁcient information to permit a formal subanalysis of
individual hormonal preparations or route of drug delivery,
although a differential effect is not evident from what data
are available. Information on dosage, adequacy, and suste-
nance of COX inhibition by patients taking aspirin or
NSAIDs are unavailable in the WHI, as was any objective
conﬁrmation of either consumption of or abstention from
such readily available COX inhibitors. Thus, we cannot
project the likely impact of our ﬁndings on the failure to
detect a cardioprotective effect of HT in WHI. However, if
this interaction is indeed clinically meaningful, we would
expect it to only partially explain such an effect. Concurrent
treatment with tNSAIDs obscured roughly one-ﬁfth of the
beneﬁt of HT in the present observational study. Finally,
given the failure to detect a cardiovascular beneﬁt of HT in
the WHI before stratiﬁcation for patient age or time since the
menopause, the failure to detect an interaction with NSAIDs
undermining such a beneﬁt [24] is unsurprising.
In summary, these observations, based on small numbers,
are provocative rather than conclusive and are not intended
to guide clinical practice, but rather to prompt additional
research. However, they raise the possibility that coincident
inhibition of COX-2 by tNSAIDs may undermine cardiopro-
tective effects of HT in peri- and postmenopausal women. If
evidence consistent with this interaction were obtained in
other larger epidemiological datasets, the possibility could
fruitfully be addressed directly in randomized controlled
clinical trials.
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Editors’ Summary
Background. There is currently a great deal of uncertainty regarding the
effect of postmenopausal hormone therapy on heart disease in women.
Premenopausal women are much less likely to experience heart attacks
and strokes than men, a difference that does not exist between
postmenopausal women and men. One mechanism that might explain
these observations relates to the effect of estrogen, which is thought to
have a protective effect on the heart. Hormone replacement therapy (HT)
consisting of replacement estrogen, and sometimes progesterone as
well, is often taken by women experiencing symptoms of menopause.
Evidence from observational studies and the Womens’ Health Initiative
(WHI) trial has suggested that HT protects against heart disease in
perimenopausal women. However, researchers have suggested that any
beneficial effect of hormone replacement therapy on the heart might be
counteracted by the effects of certain types of painkillers also being
taken by women involved in the studies. These painkillers, nonsteroidal
anti inflammatory drugs ( NSAIDs), prevent production of a molecule
called prostacyclin. Prostacyclin plays a role in preventing blood clotting
and is therefore thought to be important in protecting the heart.
Estrogen, however, acts to increase production of prostacyclin, and it is
therefore theoretically possible that hormone replacement therapy does
have a beneficial effect on heart health, but which is counteracted by the
negative effects of NSAIDs.
Why Was This Study Done? In this study, the researchers wanted to find
out whether there was any evidence for an interaction between NSAID
use, hormone replacement therapy, and heart disease. Such under-
standing in turn might help to identify more clearly whether hormone
replacement therapy protects against heart disease in specific subgroups
of postmenopausal women.
What Did the Researchers Do and Find? This study was carried out
using information from the UK’s General Practice Research Database,
which is the largest computer database of anonymous medical records
from primary care anywhere in the world. It contains information entered
by UK general practitioners on their patients’ drug prescriptions,
diagnoses, referrals to hospital, and other data. The researchers here
searched for all individuals from the database who were aged between
50 and 84 years on 1 January 1997, and then followed them up through
the database for four years, or until the individual died, reached 85 years
of age, or was diagnosed with a heart attack or cancer. From this search,
the researchers found 1,673 women who had heart attacks or who died
from coronary heart disease; these were considered ‘‘cases.’’ Then, these
1,673 women were matched against 20,000 ‘‘control’’ women of similar
age. Information was pulled out for each case or control on their use of
hormone replacement therapy, NSAIDs (covering 21 different drugs, but
most commonly diclofenac, ibuprofen, and naproxen), and various risk
factors for heart disease. The researchers then compared use of hormone
replacement therapy and NSAIDs between the cases and controls, while
making statistical adjustments for other risk factors (such as diabetes and
smoking, for example).
The researchers found that current use of hormone replacement
therapy was associated with a lower risk of heart attack than non-use.
The odds ratio (chance of a heart attack among HT users compared to
the chance among non-users of HT) was 0.78. However, when looking at
women who used NSAIDs at the same time as hormone replacement
therapy, the researchers found no suggestion of a reduction in risk of
heart attack: the odds ratio for the chance of heart attack among this
group of women, as compared to nonusers of both NSAIDs and
hormone replacement therapy, was 1.50.
What Do These Findings Mean? These findings suggest that hormone
replacement therapy and NSAIDs might interact, with NSAIDs acting
against a role for hormone replacement therapy in preventing heart
attacks. At face value, these results are in conflict with the findings of one
large trial, the WHI trial, which failed to find a benefit of HT in preventing
heart attacks. However, a recent analysis of WHI suggests cardiopro-
tective effects of HT in women close to the time of the menopause and
this coincides with the younger age of women in the observational
studies such as the present one rather than in the WHI overall.
Observational research studies, such as the present one, are often
difficult to interpret because the groups being compared are not
necessarily equivalent. It’s possible that women who take hormone
replacement therapy, or NSAIDs, are in some way different from women
who do not, which will bias the findings. Determination of the clinical
implications of these findings would most appropriately be resolved in
future trials, designed to address the question of interest.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040157.
  Resources from the US National Institutes of Health on menopausal
hormone therapy, including links to information about the Women’s
Health Initiative trials, information about managing menopausal
symptoms, and more
  Resources from the US National Institutes of Health (MedlinePlus)
about heart disease in women
  Information from NHS Direct, the UK National Health Service, about
hormone replacement therapy
  The UK General Practice Research Database is the database utilized in
this article
  Wikipedia entry on nonsteroidal anti-inflammatory drugs (NSAIDs)
(note: Wikipedia is an internet encyclopedia anyone can edit)
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